Pharma Mar (PHM) Corporate presentation summary

Strategic vision and leadership

• Focused on marine-derived oncology drugs, aiming to remain a global leader in marine medicinal innovation.

• Fully integrated commercial-stage biotech with a diversified pipeline and three approved oncology products.

• Strong European sales force and established commercial presence.

Product portfolio and pipeline

• Three approved oncology products: Yondelis (trabectedin), Aplidin (plitidepsin), and Zepzelca (lurbinectedin).

• Expanding pipeline includes late and early-stage assets, with ongoing trials in solid tumors and sarcomas.

• Lurbinectedin approved for first-line maintenance in SCLC in both US and EU, with further potential indications under study.

Clinical trial highlights

• IMforte Phase 3 trial showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) for lurbinectedin plus atezolizumab in SCLC.

• Safety profile manageable, with most adverse events not leading to discontinuation; practice-changing results noted by key opinion leaders.

• SaLuDo trial in leiomyosarcoma completed recruitment, with regulatory submissions and data readouts expected in 2026-2027.